Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

GT Biopharma Inc (GTBP)

GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,386
  • Shares Outstanding, K 1,379
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,880 K
  • 60-Month Beta 0.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.64
Trade GTBP with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( -563.31%)
  • Historical Volatility 104.70%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,089.49% on 07/19/23
  • IV Low 0.00% on 03/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 10
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 0

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -2.70
  • Number of Estimates 1
  • High Estimate -2.70
  • Low Estimate -2.70
  • Prior Year -5.41
  • Growth Rate Est. (year over year) +50.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.78 +16.65%
on 02/26/24
5.14 -14.20%
on 03/12/24
+0.14 (+3.28%)
since 02/16/24
3-Month
3.52 +25.28%
on 02/14/24
8.70 -49.31%
on 12/20/23
-3.15 (-41.64%)
since 12/18/23
52-Week
3.52 +25.28%
on 02/14/24
19.50 -77.38%
on 03/22/23
-11.49 (-72.27%)
since 03/17/23

Most Recent Stories

More News
GT Biopharma Reports Second Quarter Fiscal 2022 Financial Results and Business Update

Presented preclinical data demonstration second-generation CD19 targeting Tri-specific Killer Engager (TRIKE®) driving robust NK cell function against B...

GTBP : 4.41 (-4.75%)
Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?

Here is how Albireo Pharma (ALBO) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

ALBO : 44.15 (-0.23%)
GTBP : 4.41 (-4.75%)
Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

Here is how Aclaris Therapeutics (ACRS) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

ACRS : 1.1500 (-1.71%)
GTBP : 4.41 (-4.75%)
Has Geron (GERN) Outpaced Other Medical Stocks This Year?

Here is how Geron (GERN) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

GERN : 3.17 (-5.51%)
GTBP : 4.41 (-4.75%)
GT Biopharma Presents Preclinical Data Demonstrating Second-Generation CD19 Targeting Tri-Specific Killer Engager (TriKE®) Driving Robust NK Cell Function Against B Cell Malignancies at EHA 2022 Congress

Ongoing experiments will evaluate the functionality and efficacy of GTB-7550 in vivoFuture studies will also involve assessments of GTB-7550 TriKE efficacy...

GTBP : 4.41 (-4.75%)
GT Biopharma Reports First Quarter Fiscal 2022 Financial Results and Business Update

Presented pre-clinical data at American Association for Cancer Research (AACR 2022), demonstrating GTB-5550 (cam16-IL15-camB7H3) Tri-specific Killer...

GTBP : 4.41 (-4.75%)
GT Biopharma Presents Preclinical Data Demonstrating Novel B7H3+ Tumor Targeting GTB-5550 TriKE® Driving NK Cell Activation and ADCC Against Head and Neck Squamous Cell Carcinomas at AACR Annual Meeting 2022

- Ongoing experiments will evaluate the functionality and efficacy of the B7H3 TriKE in vivo- Future studies will also involve assessments of the B7H3...

GTBP : 4.41 (-4.75%)
Has Ensign Group (ENSG) Outpaced Other Medical Stocks This Year?

Here is how Ensign Group (ENSG) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

ENSG : 122.19 (-0.41%)
GTBP : 4.41 (-4.75%)
GT Biopharma Announces Closing of $23.7 Million Public Offering

GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage biopharmaceutical company focused on the development and commercialization of its disruptive, target-directed Natural Killer (NK) cell engager immunotherapy...

GTBP : 4.41 (-4.75%)
GT Biopharma Announces Pricing of $23,650,000 Public Offering and Uplisting to The Nasdaq Capital Market

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology platform today announced the...

GTBP : 4.41 (-4.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida.

See More

Key Turning Points

3rd Resistance Point 4.88
2nd Resistance Point 4.75
1st Resistance Point 4.58
Last Price 4.41
1st Support Level 4.28
2nd Support Level 4.15
3rd Support Level 3.98

See More

52-Week High 19.50
Fibonacci 61.8% 13.39
Fibonacci 50% 11.51
Fibonacci 38.2% 9.62
Last Price 4.41
52-Week Low 3.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar